Oncology patients have been heavily impacted by the ongoing SARS-CoV-2 pandemic. With thousands of tissue biopsies being delayed and patients postponing clinic visits, increasing access to Circulating tumour DNA (ctDNA) testing for targeted treatment selection offers another option for academic and community hospitals.

Illumina and Canexia Health invite you to a virtual discussion, on topics such as those listed below, with a panel of experts:

  • How the pandemic caused delays in screening and diagnosis of new cancer patients.
  • The impact of delayed cancer testing and late stage diagnosis.
  • Using liquid biopsy to detect actionable variants.
  • How liquid biopsy can alleviate the need for tissue biopsy and hospital visits.
  • The feasibility of implementing ctDNA tesing.
  • How to continue driving ctDNA adoption beyond the pandemic.

Details

Fill Out Form to Access Webinar

Your email address is never shared with third parties.

Date & Time
Jun 15, 2021
Topic
Oncology
Watch Now